Scale-Up of Monoclonal Antibody Production in CHO Cell Bioreactors: Process Optimisation Strategies
DOI:
https://doi.org/10.5281/zenodo.22638042Keywords:
CHO cells, monoclonal antibody, bioreactor scale-up, fed-batch, perfusion cultureAbstract
Background: Monoclonal antibodies (mAbs) produced in Chinese Hamster Ovary (CHO) cells dominate the biopharmaceutical
pipeline, and moving a productive clone into a robust, high-titre manufacturing-scale bioreactor process remains a central
engineering challenge. Objective: This article synthesises published evidence on strategies used to scale up CHO cell mAb
production and optimise the resulting bioprocess. Methods: A narrative review of published studies on CHO cell bioprocess
development, scale-up strategies, and process optimisation for mAb manufacturing, identified through PubMed, Google Scholar
and Crossref searches, restricted to individually verified sources. Findings: Reported fed-batch titres have risen from tens of
milligrams per litre in the mid-1980s to several grams per litre in contemporary processes , driven by host-cell engineering,
feed-optimised media, and intensified seed-train strategies such as N-1 perfusion . Perfusion culture using alternating tangential
flow or non-woven matrix retention sustains viable densities an order of magnitude above standard fed-batch . Scale-up relies on
qualified scale-down models and high-throughput mini-bioreactors to translate lab findings to production vessels . Process
analytical technology, including in-line Raman spectroscopy, increasingly enables real-time control of nutrients and critical
quality attributes . Conclusions: Scale-up of CHO-based mAb manufacturing is best achieved through integrated cell-line, media,
bioreactor-mode and analytical strategies validated at small scale within a quality-by-design regulatory framework.
References
Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22(11):1393-1398. doi:10.1038/nbt1026.
Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol. 2012;93(3):917-930. doi:10.1007/s00253-011-3758-5.
Lin PC, Chan KF, Kiess IA, Tan J, Shahreel W, Wong SY, Song Z. Attenuated glutamine synthetase as a selection marker in CHO cells to efficiently isolate highly productive stable cells for the production of antibodies and other biologics. mAbs. 2019;11(5):965-976. doi:10.1080/19420862.2019.1612690.
Xu J, Rehmann MS, Xu X, Huang C, Tian J, Qian NX, Li ZJ. Improving titer while maintaining quality of final formulated drug substance via optimization of CHO cell culture conditions in low-iron chemically defined media. mAbs. 2018;10(3):488-499. doi:10.1080/19420862.2018.1433978.
Xu J, Rehmann MS, Xu M, Zheng S, Hill C, He Q, Borys MC, Li ZJ. Development of an intensified fed-batch production platform with doubled titers using N-1 perfusion seed for cell culture manufacturing. Bioresour Bioprocess. 2020;7(1):17. doi:10.1186/s40643-020-00304-y.
Clincke MF, Molleryd C, Zhang Y, Lindskog E, Walsh K, Chotteau V. Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell density on the process. Biotechnol Prog. 2013;29(3):754-767. doi:10.1002/btpr.1704.
Clincke MF, Molleryd C, Samani PK, Lindskog E, Faldt E, Walsh K, Chotteau V. Very high density of Chinese hamster ovary cells in perfusion by alternating tangential flow or tangential flow filtration in WAVE bioreactor - part II: applications for antibody production and cryopreservation. Biotechnol Prog. 2013;29(3):768-777. doi:10.1002/btpr.1703.
Manahan M, Nelson M, Cacciatore JJ, Weng J, Xu S, Pollard J. Scale-down model qualification of ambr 250 high-throughput mini-bioreactor system for two commercial-scale mAb processes. Biotechnol Prog. 2019;35(6):e2870. doi:10.1002/btpr.2870.
Wiegmann V, Gardner RA, Spencer DIR, Baganz F. Equal mixing time enables scale-down and optimization of a CHO cell culture process using a shaken microbioreactor system. Biotechnol J. 2021;16(11):e2100360. doi:10.1002/biot.202100360.
Lemire L, Reyes SJ, Durocher Y, Voyer R, Henry O, Pham PL. Scale-up of a monoclonal antibody CHO fed-batch production in stirred tank bioreactors: effect of hydrodynamic conditions and feeding regimen. Biotechnol Prog. 2026;42(1):e70073. doi:10.1002/btpr.70073.
Yilmaz D, Mehdizadeh H, Navarro D, Shehzad A, O'Connor M, McCormick P. Application of Raman spectroscopy in monoclonal antibody producing continuous systems for downstream process intensification. Biotechnol Prog. 2020;36(3):e2947. doi:10.1002/btpr.2947.
Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology. 2009;19(9):936-949. doi:10.1093/glycob/cwp079.
Sou SN, Sellick C, Lee K, Mason A, Kyriakopoulos S, Polizzi KM, Kontoravdi C. How does mild hypothermia affect monoclonal antibody glycosylation? Biotechnol Bioeng. 2015;112(6):1165-1176. doi:10.1002/bit.25524.
Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv. 2012;30(5):1158-1170. doi:10.1016/j.biotechadv.2011.08.022.
Voisard D, Meuwly F, Ruffieux PA, Baer G, Kadouri A. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng. 2003;82(7):751-765. doi:10.1002/bit.10629.
Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs. 2009;1(5):443-452. doi:10.4161/mabs.1.5.9448.
Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. mAbs. 2010;2(5):466-479. doi:10.4161/mabs.2.5.12720.
Schwarz H, Lee K, Castan A, Chotteau V. Optimization of medium with perfusion microbioreactors for high density CHO cell cultures at very low renewal rate aided by design of experiments. Biotechnol Bioeng. 2023;120(9):2523-2541. doi:10.1002/bit.28397.
Liang K, Luo H, Li Q. Optimization of the process of Chinese hamster ovary (CHO) cell fed-batch culture to stabilize monoclonal antibody production and overall quality: effect of pH control strategies. Fermentation. 2024;10(7):352. doi:10.3390/fermentation10070352.
Bielser JM, Wolf M, Souquet J, Broly H, Morbidelli M. Perfusion mammalian cell culture for recombinant protein manufacturing - a critical review. Biotechnol Adv. 2018;36(4):1328-1340. doi:10.1016/j.biotechadv.2018.04.011.
Liang K, Luo H, Li Q. Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies. Front Bioeng Biotechnol. 2023;11:1112349. doi:10.3389/fbioe.2023.1112349.
Yongky A, Xu J, Tian J, Oliveira C, Zhao J, McFarland K, Borys MC, Li ZJ. Process intensification in fed-batch production bioreactors using non-perfusion seed cultures. mAbs. 2019;11(8):1502-1514. doi:10.1080/19420862.2019.1652075.
US Food and Drug Administration. Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Rockville, MD: FDA; 2004.
Konstantinov KB, Cooney CL. White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. J Pharm Sci. 2015;104(3):813-820. doi:10.1002/jps.24268.
Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733-26740. doi:10.1074/jbc.M202069200.
Langer ES, Rader RA. Single-use technologies in biopharmaceutical manufacturing: a 10-year review of trends and the future. Eng Life Sci. 2014;14(3):238-243. doi:10.1002/elsc.201300090.
Zhang JH, Shan LL, Liang F, Du CY, Li JJ. Strategies and considerations for improving recombinant antibody production and quality in Chinese hamster ovary cells. Front Bioeng Biotechnol. 2022;10:856049. doi:10.3389/fbioe.2022.856049.
